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Legislation governing genetically modiﬁed and




The European Commission’s assessment and approval process for genetically modiﬁed (GM) crops has resulted in only two GM
cropvarieties being licensed for cultivation in theEuropeanUnion, oneofwhichhasbeenwithdrawn.Unable todeﬁneGMcrops
satisfactorily, the EuropeanCommissionhas fallen back on adeﬁnitionbasedonprocess. The shortcomings of this approach are
all too clear as the Commission grapples with the advent of genome editing. This has led to a long and damaging delay in the
Commission issuing an opinion on how genome-edited crops should be regulated. At the same time, national bans imposed
by member states on GM crops without any evidence of safety concerns have been legalized. The Commission also faces the
prospect of assessing an increasing number of GM and genome-edited crops with deliberately altered composition. In this
article, the operation of regulations covering GM crops in the EuropeanUnion and the eﬀect they have had on the development
of plant biotechnology are reviewed, while the issues raised by new technologies are discussed. It is argued that there is an
urgentneed for theEuropeanUnion to shift its positiononplantbiotechnology if agriculture is tomeet the challengesof coming
decades.
© 2018 The Author. Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of
Chemical Industry.
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INTRODUCTION
Directive 2001/18/EC of the European Parliament and Council on
the deliberate release into the environment of genetically modi-
ﬁed organisms (GMOs), together with GM Food and Feed Regu-
lation (EC) No. 1829/2003, which was adopted in 2004, brought
the regulation of genetically modiﬁed (GM) crop use and release
under the control of the European Commission. The European
Union (EU) recognizes two diﬀerent types of ﬁeld release of GM
crops: one for research purposes only (a Part B release) and one
for commercial release (a Part C release). Consent for a Part C
release covers cultivation, food and feed use, but it is also pos-
sible to apply for permission for food and feed use alone (i.e.,
for import and consumption in the EU but not for cultivation).
Permission for a Part B release can be granted by an individ-
ual member state. However, applications for commercial use of
GM crops or crop products anywhere in the EU have to be
approved by the European Commission. Any food that incor-
porates a GM crop product also has to comply with stringent
labelling laws.
This review comprises the author’s opinion on how the regu-
lations on GM crops in the EU have operated, what eﬀect they
have had on the development of plant biotechnology not only
in Europe but also the rest of the world, recent changes that
have been introduced, and how regulations will be applied to
genome-edited crops and GM crops with deliberately altered
composition.
THE EU ASSESSMENT AND APPROVAL
PROCESS
An organization applying for a Part C consent to cultivate a GM
crop in the EUmust provide detailed information on the host plant
species, as well as the nature of the genetic modiﬁcation it car-
ries and the methods used to bring the modiﬁcation about. It
must also undertake an assessment of the potential risks posed to
health and/or the environment. This process begins with a com-
parison between the GM plant or food and its closest traditional
counterpart in order to establish substantial equivalence and iden-
tify any intended and unintended diﬀerences. These diﬀerences
then become the focus of the safety assessment and, if neces-
sary, further investigation. Factors taken into account in the safety
assessment include the identity and source of novel genes, the sta-
bility and potential for transfer of the novel gene or genes, the
nature of the protein encoded by the novel gene or genes, poten-
tial changes in function of novel genes and proteins in the host
background, the composition of the plant and/or food derived
from it compared with its traditional counterpart, the eﬀects of
processing and cooking, potential toxicity or allergenicity of novel
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proteins, possible secondary eﬀects resulting from expression of
the novel gene or genes, and the potential intake and dietary
impact of the introduction of the GM food. Applications for culti-
vation would also include an environmental impact assessment,
and this would be carried out by a designated member state
authority. Guidance can be found in the Codex Alimentarius, the
annex toCommission Implementing Regulation (EU)No. 503/2013
and Directive (EU) 2018/350 (a recent amendment to Directive
2001/18/EC).
Each application is assessed by the European Food Safety
Authority (EFSA) Genetically Modiﬁed Organisms (GMO) panel. If
the GMO panel’s opinion is favourable, the application is voted
on by the Commission’s Standing Committee on Plants, Animals,
Food and Feed (PAFF), with representatives from all 28 member
states. A qualiﬁed majority voting system is applied, in which
approval requires 55% of member states to vote in favour and the
supporting member states to represent at least 65% of the total
EU population. To date, more than two decades after GM crops
were ﬁrst grown commercially in the USA, only two GM crops
have been approved for cultivation in Europe: MON810, a variety
of insect-resistant (Bt) maize developed by Monsanto, as well as
some derivatives produced by local breeders under licence from
Monsanto, and the Amﬂora potato produced by BASF. Amﬂora
was engineered to contain starch consisting almost entirely of
amylopectin, resulting from the silencing of a granule-bound
starch synthase gene by RNA interference,1 and was intended for
the industrial starch market. It spent 10 years in the EU’s approval
process and, although it was ﬁnally approved in 2010, BASF pulled
out of European Biotech in 2012 and Amﬂora is now not available
anywhere.
This leaves MON810 and its derivatives as the only GM crop
varieties available to EU farmers.MON810has beengrown in Spain
since 1998, and approval for its cultivation across the EU was
granted in 2004. The area of GMmaize cultivation in Spain in 2016
was 129 081 ha,2 with approximately 7000 ha in Portugal and small
areas of cultivation in Slovakia and theCzech Republic. These areas
are tiny comparedwith the tens ofmillions of hectares of GMcrops
grown in the Americas and Asia, although the area in Spain has
been growing in recent years.
Eﬀorts to develop new GM crop varieties for cultivation in the
EU or elsewhere in Europe have now been abandoned by biotech
companies. Instead, companies are focusing on obtaining permis-
sion for foodand feedusewithout seeking approval for cultivation,
so that their potential customers elsewhere in the world can be
reassured that the Europeanmarket is open to their products. This
means that European farmers are competing with GM crops but
are unable to grow them.
DEFINITIONS
Deﬁning what GM means in the context of crop biotechnology is
not as easy as might be thought. In Directive 2001/18/EC, a genet-
ically modiﬁed organism is deﬁned as one in which the genetic
material has been altered in a way that does not occur naturally.
This raises problems because some of the techniques used in ‘tra-
ditional’ plant breeding and modern genomics produce genetic
changes that would not occur naturally. Radiation and chemi-
cal mutagenesis, for example, produce thousands of mutations in
an individual plant. The products of these treatments are consid-
ered GMOs as deﬁned by the Directive, but are granted a ‘muta-
genesis exemption’, mainly because varieties of crops with artiﬁ-
cially induced mutations were already widespread and had been
for decades when the Directive was drawn up. Oilseed rape, for
example, was only made ﬁt for human consumption through an
intensiveprogrammeofmutagenesis in the secondhalf of the20th
century that reduced the levels of erucic acid and glucosinolates,
both of which are toxic. Mutation does occur naturally, of course
(all of our major crops diﬀered greatly from their wild ancestors
long before the advent of modern plant breeding, in the main as
a result of the selection of individuals carrying naturally occurring
mutations), but not at anything like the rate induced by chemical
or radiation mutagenesis.
More recently, modern genomics techniques in plant breed-
ing have exploited doubled haploid populations for the identi-
ﬁcation of quantitative trait loci and genetic markers for marker
assisted breeding. The production of these populations involves
forced crosses between species that would not naturally inter-
breed (wheat and maize, for example), followed by chemically
induced chromosome doubling in haploid embryos that have lost
the ‘alien’ chromosomes – not very ‘natural’. Even triticale, now a
familiar crop, is a hybrid of wheat and rye that was created in a lab:
wheat and rye do not ‘naturally’ form viable hybrids. Nevertheless,
triticale and varieties of other crops produced by these methods
do not come under the EU’s GM legislation and can be marketed
in the EU without going through the safety checks and regulatory
hurdles applied to GM crops.
One possible deﬁnition of a GM crop might be that it con-
tains DNA from a sexually incompatible species. There are many
examples of this in current, highly successful GM crop varieties
on the market today. For example, the 5′-enolpyruvylshikimate
phosphate synthase (EPSPS) gene used by Monsanto to engi-
neer glyphosate tolerance in crops originated from Agrobacterium
tumefaciens,3 while the Cry genes used to impart insect resistance
in ‘Bt’ crops come from another bacterium: Bacillus thuringiensis.4
Such genes are called transgenes, and the organisms that receive
them are referred to as transgenic. The question of the ethics
of transferring genes between diﬀerent species has been raised
famously by Prince Charles, who has been quoted as saying that
‘Mixing genetic material from species that cannot breed naturally,
takes us into areas that should be left to God.’ Whatever we think
about that statement, genetic modiﬁcation does not necessarily
involve the transfer of DNA between species. For example, potato
varieties are now on the market in the USA carrying multiple traits
imparted by inserted genes derived entirely from potato. The vari-
eties have been developed by the JR Simplot Company of Boise,
Idaho, andaremarketedas Innate® and Innate® Generation2. Both
varieties have reduced expression in the tubers of an asparagine
synthetase gene, ASN1, as well as reduced expression of two
genes encoding enzymes of starch breakdown – phosphorylase
L (PhL) and starch-associated R1 (R1) – and a gene (PPO5) encod-
ing polyphenol oxidase, an enzyme involved in bruising, all as a
result of RNA interference. Innate® Generation 2 also has reduced
expression of vacuolar invertase (VInv) and increased resistance
to late blight (Phytophthora infestans) through incorporation of
the Rpi-vnt1.1 gene from Solanum venturii. The low concentration
of free asparagine and reducing sugars in the tubers of Innate®
Generation 2 is claimed to reduce the formation of acrylamide
by 90% compared with conventional potatoes. Acrylamide5 is a
processing contaminant classed by the International Agency for
Research on Cancer as a Group 2A carcinogen (probably carcino-
genic to humans). Innate® and Innate® Generation 2 are described
as cisgenic rather than transgenic, and this distinction has been
prominent in thepromotionalmaterial that has accompanied their
release.
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It has been argued that cisgenic plants should not come under
GM regulations.6 If such a distinction between transgenic and cis-
genic were to be made, the question would then arise as to how
close a relative to a crop species must a source species be for
a gene to qualify as a cisgene rather than a transgene. The late
blight resistance gene, Rpi-vnt1.1, that is present in Innate® Gen-
eration 2, for example, originated from a wild potato: Solanum
venturii7 – deﬁnitely a potato species, but not the same species as
cultivated potato: Solanum tuberosum. However, currently this is a
moot point because the notion that cisgenic plants should not be
regulated in the sameway as transgenics has so far been rejected.8
Of course, whether cisgenic or transgenic, the introduced gene
will have inserted into the host genome by DNA recombina-
tion, but DNA recombines naturally all of the time, so the pres-
ence of recombinant DNA itself cannot be used as a deﬁnition
of a GMO.
Given all of the above, the European Commission cannot use its
own oﬃcial deﬁnition of a GMO (an organism in which the genetic
material has been altered in a way that does not occur naturally)
when considering whether a new crop variety should have to go
through its approval process for GM crops, or deﬁne a GMO as an
organism containing a foreign gene or recombinant DNA. It has
therefore fallen back on deﬁning a GMO based on the processes
used toproduce it. As far asGMplants go, thatmeansplants regen-
erated from cells or protoplasts following Agrobacterium tumefa-
ciens-mediated transformation, plants grown from seeds that have
been transformed by Agrobacterium tumefaciens using the ﬂoral
dipmethod, plants arising fromdirect transfer of agene intoproto-
plasts using polyethylene glycol or electroporation, or direct trans-
fer of agene intoplantmaterial byparticle bombardmentor silicon
carbide ﬁbre vortexing. It was inevitable that this approach would
cause problems as new technological advances were made.
NEWMETHODS, NEW PROBLEMS: GENOME
EDITING
The last decade has seen the emergence of a raft of techniques
that have been given the umbrella term of genome (or gene)
editing because they are used to make mutations in speciﬁc tar-
get genes in a plant’s genome. These technologies use specially
designed oligonucleotides (oligonucleotide-directed mutagene-
sis, or ODM), or targeted nucleases such as zinc-ﬁnger nucle-
ases (ZFN), meganucleases, transcription activator-like eﬀector
nucleases (TALENs) or components of a bacterial defence sys-
tem based on clustered, regularly interspaced, short palindromic
repeats (CRISPR) and the Cas9 nuclease. Those involving targeted
nucleases have up to now required a GM step to introduce a gene
encoding the nuclease, and in the case of CRISPR-Cas9 a guide
RNA, into the host plant genome. However, once themutation has
beenmade the transgene can be eliminated by ‘selﬁng’ the edited
plant and selecting progeny that carry the gene edit but not the
transgene. Furthermore, techniques are being developed to intro-
duce the nuclease directly into plant cells, bypassing the GM step.
In their most common usage, genome editing techniques intro-
duce a ‘knock-out’ mutation in the target gene, in the form of a
short deletion. More sophisticated applications are being devel-
oped, but certainly when used in its simplest form there is no sci-
entiﬁc justiﬁcation for treating a genome-edited plant diﬀerently
fromaplant producedbyothermutagenesis techniques, or a plant
that has arisen through natural mutation.
That certainly appears to be the view of the US Department of
Agriculture (USDA), which has stated that it will not regulate a
mushroom that has been editedwith CRISPR-Cas9, the ﬁrst case of
a genome-edited food crop that has come before it (albeit a fun-
gus, not a plant). The USDA also issued a press release on 28March
2018 stating that it does not have any plans to regulate plants pro-
duced by genome editing that are indistinguishable from those
developed through traditional breeding methods, as long as they
are not plant pests or developed using plant pests (https://www
.usda.gov/media/press-releases/2018/03/28/secretary-perdue-
issues-usda-statement-plant-breeding-innovation). Argentina
has also developed policies for genome-edited plants (Reso-
lution No. 173/2015), essentially saying that new varieties will
be assessed on a case-by-case basis, but that if there is no new
combination of genetic material and no transgenes have been
used the product will not be regulated as a GMO. In Canada, plants
with ‘novel traits’ are covered by the Plant Protection Act (1990),
regardless of the technology used to produce them, and the cul-
tivation of a sulfonylurea-tolerant oilseed rape variety produced
by ODM was approved by the Canadian Food Inspection Agency
as long ago as 2013 (http://www.inspection.gc.ca/plants/plants-
with-novel-traits/approved-under-review/decision-documents/
dd-2013-100/eng/1427383332253/1427383674669). In contrast,
the European Commission has deferred a decision on the regula-
tion of genome-edited plants to an unspeciﬁed future date. This
is extremely damaging because European plant breeders will not
invest in the technologywithout clarity on the regulatory situation.
There are some grounds for optimism that the situation is about
to change: in January 2018, an Advocate General of the European
Court of Justice, which is responsible for interpreting EU law and
ensuring its equal application across the EU, issued an opinion
(Opinion Case C-528/16) on proceedings brought by Confédéra-
tion Paysanne, a French farmers’ union, and others, who sought
an annulment of the mutagenesis exemption. The Advocate Gen-
eral reasserted that organisms obtained bymutagenesis are GMOs
within the meaning of Directive 2001/18/EC, but went on to state
that themutagenesis exemptionapplied to all organismsobtained
by any technique of mutagenesis, on condition that they do not
contain recombinant nucleic acidmolecules. Ignoring the fact that
all organisms naturally contain recombinant DNA, this judgement
would appear togive thego-ahead to thegenomeeditingof crops,
as long as no transgene is present in the edited plants. The mat-
ter will now be considered by a judge, or panel of judges, but the
opinions reachedby the court’s AdvocatesGeneral are usually very
inﬂuential and are followed in the majority of cases.
NEW TRAITS, NEW PROBLEMS: GM CROPS
WITH DELIBERATELY ALTERED COMPOSITION
The European Commission also faces the prospect of having to
adapt its processes to the risk assessment of GM crops, foods and
feeds with deliberately altered composition. As described above,
the Commission’s current risk assessment strategy, as applied by
EFSA’s GMO Panel, is based on the principle of substantial equiv-
alence, in which GM crops and their derived food and feeds are
compared with a conventional, non-GM comparator. That is ﬁne
when the GM trait carried by a variety imparts herbicide tolerance,
or resistance to disease or insects, but recent years have seen the
development of GM crop varieties that have received deliberate
modiﬁcations to their composition. Mavera maize, for example,
whichwas developed by Renessen, a joint venture betweenCargill
and Monsanto, combines a triple stack of input traits (resistance
to corn rootworm and the European corn borer, and tolerance
of glyphosate) with high lysine content as the cherry on top. The
wileyonlinelibrary.com/jsfa © 2018 The Author. J Sci Food Agric 2019; 99: 8–12
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Vistive soybean variety developed by DuPont, the oil from which
has increased levels of oleic acid and reduced polyunsaturated
fatty acids, increasing its shelf life and making it more stable
during high-temperature processing,9 is another example, as are
the Innate® and Innate® Generation 2 potato varieties discussed
above.
The Amﬂora potato variety also came into this class of GM crops
and, unlike the three examples above, was intended for cultivation
in Europe. The diﬃculties that the European Commission had in
risk assessing Amﬂora and the prospect of having to deal with an
increasing number of crops with altered composition highlighted
the need for robust, workable processes for the safety assessment
of GM crops with altered composition.
Up to that point, EFSA’s position was that ‘Where no compara-
tor can be identiﬁed, a comparative risk assessment cannot be
made and a comprehensive safety and nutritional assessment of
the GM plant and derived food and feed itself should be carried
out.’ A team of scientists (of which the author was a member) was
commissioned to review this position and concluded that compar-
ative approaches based on the concept of substantial equivalence
were the basis of all current risk assessment strategies across the
world, whether or not the composition of the crop had been delib-
erately altered.10,11 Indeed, GM varieties with deliberately altered
composition that had already been approved in theUSA and other
countries outside the EU had been risk assessed using the same
framework as thosewith input traits,withno speciﬁcmodiﬁcations
to risk assessment criteria. It remains to be seen whether the Euro-
pean Commission will adopt this approach.
DEVOLUTION OF DECISION-MAKING TO
MEMBER STATES
It has been extremely diﬃcult to get agreement on GM crop
approvals from all European Union member states ever since the
process was brought under the control of the European Com-
mission. The qualiﬁed majority voting system and the implaca-
ble anti-GM position of some member states, which meant that
they voted against any GM crop approval regardless of the rec-
ommendation of the EFSA GMO Committee, arguably made the
process dysfunctional. Evenwhenapprovalsweregranted, individ-
ual member states continued to impose their own bans. Under EU
law, member states were only allowed to impose bans for safety
reasons, for example if a GM crop posed a risk to the environ-
ment in that member state that it did not pose elsewhere. As it
was, member states were imposing bans without any evidence of
safety issues, ﬂouting EU treaties and putting themat loggerheads
with theEuropeanCommission. In 2006, theWorldTradeOrganiza-
tion ruled that the EU’s position was illegal and criticized the bans
imposed by individual member states.12
In order to resolve this lamentable situation, the European
Commission proposed that some of the decision making on GM
crop and food issues should be devolved back down to national
member state governments, and in March 2015 proposals were
approved for anewsystemofGMcropauthorizations. Thenewsys-
tem allows member states to request, via the Commission, that a
company applying for approval of a GM crop adjust the geograph-
ical scope of its application to exclude a particular member state
or region. If the applicant refuses to adjust the geographical scope
of its authorization, member states are allowed to proceed with
national bans. In simple terms, this allows member states to opt
out of allowing cultivation or import of a GM crop that has been
approved at EU level, without giving a reason, eﬀectively legaliz-
ing the previously illegal bans imposed by some member states.
Almost immediately, 15 member states told the European Com-
mission that they would send territorial exclusion requests for any
application to market a GM crop for cultivation. These countries
were Austria, Bulgaria, Croatia, Cyprus, Denmark, France, Germany,
Greece, Hungary, Italy, Latvia, Lithuania, the Netherlands, Poland
and Slovenia. In addition, Scotland, Northern Ireland and Wales
said they would opt out on a regional basis, as did Wallonia (the
French-speaking region of southern Belgium).
WHAT IS THE EUMISSING OUT ON?
The worldwide area of land planted with GM crops in 2016 was
185million hectares,2 representing approximately 12% of total
world agriculture. More than three-quarters (78%) of global soy-
bean production was GM, with ﬁgures of 64%, 26% and 24% for
cotton, maize and oilseed rape, respectively. Other crops with
someGMvarieties beinggrowncommercially included sugar beet,
alfalfa, papaya and poplar. GM crops were grown in 26 coun-
tries, with the USA, Brazil, Argentina, Canada, India, Paraguay, Pak-
istan, China, South Africa, Uruguay and Bolivia all planting more
than a million hectares of GM crops. In contrast, only 136 000 ha
were planted in the whole of the EU, despite the fact that the EU
imported tens of millions of tonnes of GM soybean, maize and
other crops for use in animal feed.
The most popular traits introduced by GM are undoubtedly her-
bicide tolerance and insect resistance, but there are also traits
imparting virus or fungal/oomycete disease resistance, and traits
aﬀecting fruit ripening, oil content, starch composition, resistance
to bruising, nutritional value and food safety. The Innate® Genera-
tion 2 potato variety discussed already in this article shows where
crop biotechnology is heading in the USA, with multiple quality
traits aswell as resistance to late blight disease, and improved con-
sumer safety as amajor sellingpoint. There is currently noprospect
of similar varieties being grown in the EU, highlighting how far
behind crop biotechnology is in Europe compared with the USA,
and how this is beginning to compromise eﬀorts to improve food
safety.
CONCLUSIONS
It is highly unlikely that any biotech company will attempt to
develop a GM crop for cultivation in the EU while the current
regulatory system is in operation. This is not only aﬀecting the
competitiveness of European agriculture but, because the EU is
the biggest commodity market in the world, EU regulations and
European attitudes are a wet blanket for countries that supply
it, with many African countries that would beneﬁt hugely from
GM crops afraid to adopt them for fear of losing access to the EU
market.
It is vital that European attitudes change and over-regulation
is rolled back, because agriculture faces huge challenges in the
coming decades, including inadequate supplies of freshwater, the
advent of peak oil (the point when the maximum rate of global
petroleumextraction is reached, afterwhich the rate of production
enters terminal decline), competition for land use, soil erosion,
salination and pollution. Plant breeding will not be able to play
its full part in meeting these challenges if some technologies are
rendered unusable for no rational reason. However, it is diﬃcult to
see where the drive for change will come from.
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